Brain Cancer

No Survival Gains Seen with Nimotuzumab in Glioblastoma but More Study Warranted in Patients with MGMT Nonmethylated Glioblastoma

Nimotuzumab does not improve survival among newly diagnosed glioblastoma patients when added to standard temozolomide chemoradiotherapy, but warrants further study among patients with MGMT nonmethylated glioblastoma, according to a randomized multicenter phase 3 study reported at the 2012 American Society of Clinical Oncology Annual Meeting.

Next post in Skin Cancer